Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

20-09-2016 | Endocrine cancers | Book chapter | Article

31. Surgical Approach to Papillary Thyroid Cancer

Author: Gerard M. Doherty, MD, FACS

Publisher: Springer New York

Login to get access

Abstract

Papillary thyroid cancer has an excellent prognosis, with few deaths from disease compared to most solid tumors. The measures of quality intervention depend more upon outcomes other than survival, disease-free survival, quality of life, complications from therapy, and the need for ongoing surveillance or treatment, which are all interrelated. To be most effective by these measures, operative treatment for papillary thyroid cancer should be thorough without morbidity and tailored to the specific patient situation.
Literature
1.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov Y, Pacini F, Randolph G, Sawka A, Shepard D, Sosa J, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Available online at Thyroid 25: DOI:10.1089/thy.2015.0020; print version in Thyroid 26:1–133, 2016.
2.
Kouvaraki MA, Lee JE, Shapiro SE, Sherman SI, Evans DB. Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery. 2004;136(6):1183–91.CrossRefPubMed
3.
Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer [see comment]. Ann Surg. 2007;246(3):375–81; discussion 381–374.CrossRefPubMedPubMedCentral
4.
Doherty GM. Prophylactic central lymph node dissection: continued controversy [comment]. Oncology. 2010;23(7):603, 608.
5.
Hughes DT, White ML, Miller BS, Gauger PG, Burney RE, Doherty GM. Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery. 2010;148(6):1100–6; discussion 1006–1107.CrossRefPubMed
6.
Dralle H, Sekulla C, Lorenz K, Brauckhoff M, Machens A, German ISG. Intraoperative monitoring of the recurrent laryngeal nerve in thyroid surgery. World J Surg. 2008;32(7):1358–66.CrossRefPubMed
7.
Olson Jr JA, DeBenedetti MK, Baumann DS, Wells Jr SA. Parathyroid autotransplantation during thyroidectomy. Results of long-term follow-up [see comment]. Ann Surg. 1996;223(5):472–8; discussion 478–80.CrossRefPubMedPubMedCentral